Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends two drugs for ovarian cancer but rejects three

Paclitaxel and Caelyx given preliminary nod
NICE

NICE has recommended paclitaxel and Jansen-Cilag's Caleyx for the treatment of ovarian cancer in draft guidance.

Both paclitaxel and Caelyx (pegylated liposomal doxorubicin hydrochloride) are recommended as monotherapy and also in combination with platinum-based therapies.

But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.

Hycamtin was also provisionally not recommended for treating cancer that has returned within six months of treatments with a platinum-based regimen or cancer that does not respond to platinum treatment at all.

Meindert Boysen, NICE programme director of appraisals, said: “NICE makes difficult decisions to ensure that people using the NHS get access to the most cost-effectiveness treatments, and to help the NHS to share its resources fairly.

“This draft guidance recommends paclitaxel and pegylated liposomal doxorubicin hydrochloride for the treatment of ovarian cancer that has returned after previous treatment with platinum chemotherapy. 

“However the independent committee found that the evidence on the further three drugs indicated that they didn't provide enough extra health benefit for the cost to the NHS.”

Ovarian cancer is a common gynaecological cancer. The most common type of ovarian cancer arises from epithelial cells (the outside layer of cells) on the surface of the ovary, and can often spread from the ovary to any surface within the abdominal cavity including the fallopian tubes and peritoneal cavity.

Ovarian cancer predominantly occurs in older women, with over 80% of cases being diagnosed in women over 50 years. In 2010, around 7,000 new cases of ovarian cancer were diagnosed. 

Article by
Nikhil Patel

26th November 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Article
How will COVID-19 affect uptake of vaccinations against other diseases?...
Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal
Even after the pandemic is long behind us, virtual collaboration will become mainstay in Pharma....
Podcast
Living With Chronic Illness (Series one)...

Infographics